Cenobamate

Unassigned

New Medicines

Partial focal epilepsy - adjunctive therapy

Information

New molecular entity
SK Bio-Pharmaceuticals
SK Bio-Pharmaceuticals

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

A sodium channel blocker, with a binding site different from that of classical sodium channel blocking drugs and it enhances GABAergic transmission by increasing presynaptic GABA release.
Incidence is estimated to be 50 per 100,000 per year and the prevalence of active epilepsy in the UK is estimated to be 5–10 cases per 1000 [1].
Partial focal epilepsy - adjunctive therapy
Oral

Evidence based evaluations